The relationship of urotensin II with insulin resistance and hs-CRP in patients having PCOS

References

• Ehrmann DA. Polycystic ovary syndrome. N Engl J Med 2005;352:1223–36
   PubMed Web of Science ®Google Scholar
• Marshall JC, Dunaif A. Should all women with PCOS be treated for insulin resistance? Fertil Steril 2012;97:18–22
   PubMed Web of Science ®Google Scholar
• Mani H, Levy MJ, Davies MJ, et al. Diabetes and cardiovascular events in women with polycystic ovary syndrome: a 20 years retrospective cohort study. Clin Endocrinol (Oxf) 2012;78:926--34
   Google Scholar
• Coviello AD, Legro RS, Dunaif A. Adolescent girls with polycystic ovary syndrome have an increased risk of the metabolic syndrome associated with increasing androgen levels independent of obesity and insulin resistance. J Clin Endocrinol Metab 2006;91:492–7
   PubMed Web of Science ®Google Scholar
• Glueck CJ, Papana R, Wang P, et al. Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. Metabolism 2003;52:908–15
   PubMed Web of Science ®Google Scholar
• Toulis KA, Goulis DG, Mintziori G, et al. Meta-analysis of cardiovascular disease risk markers in women with polycystic ovary syndrome. Hum Reprod Update 2011;17:741–60
   PubMed Web of Science ®Google Scholar
• Chatenet D, Nguyen TT, Létourneau M, Fournier A. Update on the urotensinergic system: new trends in receptor localization, activation, and drug design. Front Endocrinol (Lausanne) 2013;3:1–13
   Google Scholar
• Silvestre RA, Egido EM, Hernández R, et al. Urotensin-II is present in pancreatic extracts and inhibits insulin release in the perfused rat pancreas. Eur J Endocrinol 2004;151:803–9
   PubMed Web of Science ®Google Scholar
• Wang HX, Zeng XJ, Liu Y, et al. Elevated expression of urotensin II and its receptor in skeletal muscle of diabetic Mouse. Regul Pept 2009;154:85–90
   Google Scholar
• Clozel M, Hess P, Qiu C, et al. The urotensin-II receptor antagonist palosuran improves pancreatic and renal function in diabetic rats. J Pharmacol Exp Ther 2006;316:1115–21
   PubMed Web of Science ®Google Scholar
• Zhu YC, Zhu YZ, Moore PK. The role of urotensin II in cardiovascular and renal physiology and diseases. Br J Pharmacol 2006;148:884–901
   PubMed Web of Science ®Google Scholar
• Ong KL, Wong LY, Cheung BM. The role of urotensin II in the metabolic syndrome. Peptides 2008;29:859–67
   PubMed Web of Science ®Google Scholar
• Ross B, McKendy K, Giaid A. Role of urotensin II in health and disease. Am J Physiol Regul Integr Comp Physiol 2010;298:1156–72
   PubMed Web of Science ®Google Scholar
• Ong KL, Wong LY, Man YB, et al. Haplotypes in the urotensin II gene and urotensin II receptor gene are associated with insulin resistance and impaired glucose tolerance. Peptides 2006;27:1659–67
   PubMed Web of Science ®Google Scholar
• Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19:41–7
   PubMed Web of Science ®Google Scholar
• Katz A, Nambi SS, Mather K, et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000;85:2402–10
   PubMed Web of Science ®Google Scholar
• Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412–19
   PubMed Web of Science ®Google Scholar
• Totsune K, Takahashi K, Arihara Z, et al. Elevated plasma levels of immunoreactive urotensin II and its increased urinary excretion in patients with Type 2 diabetes mellitus: association with progress of diabetic nephropathy. Peptides 2004;25:1809–14
   PubMed Web of Science ®Google Scholar
• Suguro T, Watanabe T, Kodate S, et al. Increased plasma urotensin-II levels are associated with diabetic retinopathy and carotid atherosclerosis in Type 2 diabetes. Clin Sci (Lond) 2008;115:327–34
   PubMed Web of Science ®Google Scholar
• Totsune K, Takahashi K, Arihara Z, et al. Increased plasma urotensin II levels in patients with diabetes mellitus. Clin Sci (Lond) 2003;104:1–5
   PubMed Web of Science ®Google Scholar
• Gruson D, Rousseau MF, Ketelslegers JM, Hermans MP. Raised plasma urotensin II in type 2 diabetes patients is associated with the metabolic syndrome phenotype. J Clin Hypertens (Greenwich) 2010;12:653–60
   PubMed Web of Science ®Google Scholar
• Suzuki S, Wenyi Z, Hirai M, et al. Genetic variations at urotensin II and urotensin II receptor genes and risk of type 2 diabetes mellitus in Japanese. Peptides 2004;25:1803–8
   PubMed Web of Science ®Google Scholar
• Wenyi Z, Suzuki S, Hirai M, et al. Role of urotensin II gene in genetic susceptibility to Type 2 diabetes mellitus in Japanese subjects. Diabetologia 2003;46:972–6
   PubMed Web of Science ®Google Scholar
• Sidharta PN, Rave K, Heinemann L, et al. Effect of the urotensin-II receptor antagonist palosuran on secretion of and sensitivity to insulin in patients with Type 2 diabetes mellitus. Br J Clin Pharmacol 2009;68:502–10
   PubMed Web of Science ®Google Scholar
• Watson AM, Olukman M, Koulis C, et al. Urotensin II receptor antagonism confers vasoprotective effects in diabetes associated atherosclerosis: studies in humans and in a mouse model of diabetes. Diabetologia 2013;56:1155--65
   Google Scholar
• Xie N, Liu L. Elevated expression of urotensin II and its receptor in great artery of type 2 diabetes and its significance. Biomed Pharmacother 2009;63:734–41
   Google Scholar
• Bousette N, Patel L, Douglas SA, et al. Increased expression of urotensin II and its cognate receptor GPR14 in atherosclerotic lesions of the human aorta. Atherosclerosis 2004;176:117–23
   PubMed Web of Science ®Google Scholar
• Zhao J, Ding W, Song N, et al. Urotensin II-induced collagen synthesis in cultured smooth muscle cells from rat aortic media and a possible involvement of transforming growth factor-β1/Smad2/3 signaling pathway. Regul Pept 2013;182:53–8
   Google Scholar
• Silva D, Pais de Lacerda A. High-sensitivity C-reactive protein as a biomarker of risk in coronary artery disease. Rev Port Cardiol 2012;31:733–45
   PubMedGoogle Scholar
• Gilstrap LG, Wang TJ. Biomarkers and cardiovascular risk assessment for primary prevention: an update. Clin Chem 2012;58:72–82
   PubMed Web of Science ®Google Scholar